Epstein-Barr virus transmission via the donor organs in solid organ transplantation: polymerase chain reaction and restriction fragment length polymorphism analysis of IR2, IR3, and IR4

Cen, Han; Breinig, Mary C.; Atchison, Robert W.; Ho, Monto; Mcknight, J. L. C.

doi:10.1128/jvi.65.2.976-980.1991

Cited by 113 publications

(23 citation statements)

References 19 publications

(21 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, Epstein-Barr virus (EBV)-associated lymphoproliferative disease has been seen with both AIDS and organ transplantation and the incidence does not appear to be reduced by HAART. 32,33 Furthermore, human herpesvirus (HHV)-8 may be related to the development of Kaposi's sarcoma. 34,35…”

Section: Risk Of Infections/cancermentioning

confidence: 99%

Donor Infection: An Opinion on Lung Donor Utilization

Garrity

Boettcher

Gabbay

2005

The Journal of Heart and Lung Transplantation

View full text Add to dashboard Cite

Section: Risk Of Infections/cancermentioning

confidence: 99%

Donor Infection: An Opinion on Lung Donor Utilization

Garrity

Boettcher

Gabbay

2005

The Journal of Heart and Lung Transplantation

View full text Add to dashboard Cite

“…Unlike in the non-immunocompromised healthy person, EBV poses a significant threat to kidney transplant recipients, adversely affecting both patient and graft survival. 1 Recipients exposed to EBV for the first time after transplant, often via the donor organ, 2 have the risk of post-transplant lymphoproliferative disorders with polyclonal polymorphic B lymphocyte hyperplasia, which can lead to malignancy.…”

Section: Introductionmentioning

confidence: 99%

Transplantation of solid organ recipients shedding Epstein‐Barr virus DNA pre‐transplant: A prospective study

Verghese

Schmeling

Filtz

et al. 2017

Clinical Transplantation

View full text Add to dashboard Cite

Epstein-Barr virus (EBV) poses a significant threat to patient and graft survival post-transplant. We hypothesized that recipients who shed EBV at transplant had less immunologic control of the virus and hence were more likely to have active EBV infection and disease post-transplant. To test this hypothesis, we conducted a 5-year prospective study in primary solid organ transplant recipients. We measured EBV DNA in oral washes and blood samples by quantitative PCR before transplant and periodically thereafter for up to 4 years. Pre-transplant samples were available from 98 subjects. EBV DNA was detected pre-transplant in 32 of 95 (34%) and 5 of 93 subjects (5%) in oral wash and blood, respectively. Recipients with and without detectable pre-transplant EBV DNA were not significantly different demographically and had no significant difference in patient and graft survival (P = .6 for both comparisons) or post-transplant EBV viremia-free survival (P = .8). There were no cases of EBV-related disease or post-transplant lymphoproliferative disorder (PTLD) in any of the patients with detectable EBV DNA pre-transplant. In conclusion, detectable EBV DNA pre-transplant was not associated with differences in patient/graft survival, post-transplant EBV viremia, or EBV-related diseases including PTLD.

show abstract

“…Epstein-Barr virus (EBV) infects and establishes latency in B lymphocytes (for reviews, see references 12, 15, and 27). The virus has been implicated in the etiology of malignancies such as Burkitt's lymphoma (BL) (6,11,18,28) and in lymphoproliferative diseases in the immunocompromised host, including posttransplant lymphoproliferative disorders (PTLDs) and AIDS-related lymphomas (1,2,8,10,16,25,28). The high rate of mortality associated with the development of PTLDs has prompted several groups to retrospectively analyze EBV load in peripheral blood, virus shedding, localization of in situ markers for virus (by using an EB-encoded RNA [EBER] probe), and the anti-EBNA specific antibody responses in efforts to identify prognostic markers of disease (14,19,20,31).…”

mentioning

confidence: 99%

Use of quantitative competitive PCR to measure Epstein-Barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders

et al. 1997

View full text Add to dashboard Cite

A quantitative competitive PCR (QC-PCR) assay for Epstein-Barr virus (EBV) has been developed to provide accurate measurement of EBV genome load in pediatric transplant recipients at risk for developing posttransplant lymphoproliferative disorder (PTLD). The assay quantifies between 8 and 5,000 copies of the EBV genome in 10(5) lymphocytes after a 30-cycle amplification reaction. For 14 pediatric patients diagnosed with PTLD, the median EBV genome load was 4,000, and 13 of the 14 patients had values of >500 copies per 10(5) lymphocytes. Only 3 of 12 control transplant recipients not diagnosed with PTLD had detectable viral genome loads (median value, 40). This median was calculated by using the highest value obtained by PCR testing on each of these patients posttransplantation. PCR values of >500 copies per 10(5) lymphocytes appear to correlate with a diagnosis of PTLD. By a modified protocol, the EBV genome copy number in latently infected adults was estimated to be <0.1 copy per 10(5) lymphocytes.

show abstract

Epstein-Barr virus transmission via the donor organs in solid organ transplantation: polymerase chain reaction and restriction fragment length polymorphism analysis of IR2, IR3, and IR4

Cited by 113 publications

References 19 publications

Donor Infection: An Opinion on Lung Donor Utilization

Donor Infection: An Opinion on Lung Donor Utilization

Transplantation of solid organ recipients shedding Epstein‐Barr virus DNA pre‐transplant: A prospective study

Use of quantitative competitive PCR to measure Epstein-Barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders

Contact Info

Product

Resources

About